Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

February 15, 2020

Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.

February 15, 2020

Eileen O'Reilly, MD, discusses the utility of PARP inhibitors in pancreatic cancer.

February 14, 2020

Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.

February 11, 2020

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

February 11, 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

February 08, 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

February 07, 2020

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).

February 07, 2020

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

February 07, 2020

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

January 31, 2020

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

January 24, 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

January 24, 2020

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

January 23, 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

January 21, 2020

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

January 17, 2020

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

January 16, 2020

Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

January 15, 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

January 13, 2020

Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.

January 11, 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

January 11, 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.